(Q43801239)

26 November 2017

0 references

Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia (English)

1 reference

26 November 2017

1

Boyle P

1 reference

26 November 2017

Robertson C

2

1 reference

26 November 2017

Manski R

series ordinal

3

1 reference

26 November 2017

Padley RJ

series ordinal

4

1 reference

26 November 2017

Roehrborn CG

series ordinal

5

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

26 November 2017

1 reference

26 November 2017

volume

58

1 reference

26 November 2017

issue

5

1 reference

26 November 2017

page(s)

717-722

1 reference

Medical therapy for benign prostatic hyperplasia: a review of the literature

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

Benign prostatic hyperplasia. Current pharmacological treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

Validation of a symptoms questionnaire for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

A general parametric approach to the meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

Bayesian approaches to random-effects meta-analysis: a comparative study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

Meta-analysis of published clinical trials of a ribosomal vaccine (ribomunyl) in prevention of respiratory infections

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901344-9

7 January 2021

10.1016/S0090-4295(01)01344-9

Identifiers

DOI

1 reference

26 November 2017

1 reference